Key result
Targeted nanomedicines offer a promising platform for the prophylaxis and treatment of thrombosis by increasing local drug effects and decreasing systemic bleeding complications.
Why the study?
Conventional anti-thrombotic therapy carries severe bleeding risks such as cerebral hemorrhage and stroke, prompting targeted nanomedicine approaches to enhance local efficacy and reduce systemic exposure.
Targeted nanotherapeutics represent a promising emerging strategy to improve the efficacy and reduce the bleeding risks of anti-thrombotic therapy.
Should not change antithrombotic practice; leaves open the need for clinical trials of targeted nanomedicines.
Currently available anti-thrombotic therapy for the prophylaxis and treatment of arterial and venous thrombosis includes intravenous administration of anti-thrombotic drugs which lead to severe bleeding risks such as cerebral hemorrhage and stroke. Targeting approaches that utilize nanosystems to reach the thrombus sites are emerging to increase the local effect of anti-thrombotic drugs, as well as to decrease these severe bleeding complications by diminishing the systemic availability of these drugs. This review emphasizes the emerging targeted nanomedicines (liposomes, micelles, polymeric nanoparticles, material bases nanoparticles and other biological vectors) for the prophylaxis and treatment of thrombotic events as well as multifunctional nanomedicines for theranostic applications. Nanomedicine offers a promising platform for a smart, safe, and effective approach for the management of thrombosis.
No takes yet. Share an insight, caveat, or question.
Priya et al. (2021) conducted a review in Thrombosis. Targeted nanomedicines was evaluated. Targeted nanomedicines offer a promising platform for the prophylaxis and treatment of thrombosis by increasing local drug effects and decreasing systemic bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: